PD-L1 expression levels in tumors have been used as a predictive biomarker for response to immune checkpoint inhibitors in several cancer types, including melanoma, non-small cell lung cancer, bladder cancer, and colorectal cancer [68,69,70]. Here, CD274 is linked to melanoma.